GILD 1Q19 HCV sales=$790M, +7% QoQ: http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-first-quarter-2019-financial-results GILD’s 1Q19 US HCV sales were $393M, -6% QoQ; GILD’s 1Q19 ex-US HCV sales were $397M, +25% QoQ.